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Sununary 
Factors that induce proliferation of the human hematopoietic stem cell are ill-defined. Primitive 
hematopoietic progenitors can be maintained and differentiate in stroma-dependent, long-term 
bone marrow cultures (LTBMC), originally described by Dexter et al. (Dexter,  T. M., L. H. 
Coutinho, E. Spooncer, C. M. Heyworth, C. P. Daniel, R. Schiro, J. Chang, and T. D. Allen. 
1990. Molecular Control of Haemopoiesis). However, 70-80% of primitive progenitors capable 
of reinitiating secondary stromal cultures (LTBMC-initiating cells [IC]) are lost over a period 
of 5 wk in such cultures. We have recently described a novel "stroma-noncontact" culture system, 
in which hematopoietic progenitors are separated from the stromal layer by a 0.4-/~m microporous 
filter membrane. Primitive progenitors in such cultures can not only differentiate into committed 
progenitors, but are also maintained to a greater extent than in "Dexter" cultures. However, 
still only 50% of the originally seeded LTBMC-IC are recovered at week 5. Since maintenance 
of primitive progenitors may depend not only on growth-promoting factors but also on factors 
that inhibit differentiation and/or proliferation, we evaluated the effect of macrophage inflammatory 
protein 1 ol (MIP-lo  0 or "stem cell inhibitor'" in combination with the growth-inducing factor 
interleukin 3  (IL-3)  on  the recovery  of LTBMC-IC from stroma-noncontact cultures.  We 
demonstrate that addition of MIP-lot alone to stroma-noncontact cultures does not change the 
number of LTBMC-IC present after 8 wk, indicating that this factor may not directly inhibit 
or stimulate proliferation of primitive progenitors. Addition of the growth stimulatory cytokine, 
IL-3, alone results in exhaustion of LTBMC-IC after 8 wk of culture, possibly as a result of 
their terminal differentiation. However, LTBMC-IC can be maintained for at least 8 wk when 
grown in stroma-noncontact cultures supplemented with both MIP-lc~ plus IL-3.  This effect 
depends on soluble (ill-defined)  stromal factors,  and results  from a direct interaction of these 
cytokines with the progenitor population or its progeny, but not the stroma. 
M 
echanisms that govern induction of a quiescent state, 
proliferation, and differentiation of primitive human 
hematopoietic progenitors, are not well understood. In vivo, 
hematopoiesis takes place in close proximity with the bone 
marrow microenvironment where hematopoietic stem cells 
reside, usually in Go, and occasionally proliferate and differen- 
tiate into more mature precursors.  In vitro, this process is 
mimicked relatively closely in stroma-dependent, long-term 
bone marrow cultures (LTBMC)  1, originally described by 
Dexter et al. (1). It is thought that proliferation of primitive 
1 Abbreviations used in thispalx~ BM, bone marrow; CFC, colony-forming 
cell; IC, initiating  cell; LDA, limiting  dilution  analysis; LIF, leukemia 
inhibitory factor;  LTMBC,  long-term bone marrow culture;  MlP-lc~, 
macrophage inflammatory  protein  lcq rHu, recombinant  human;  SCF, 
stem cell factor. 
progenitors in these cultures is the result of the relative avail- 
ability of both growth-promoting cytokines, which can be 
induced by a variety of stimuli, and the negative influence 
of growth inhibitory cytokines such as TGF-~ (2). However, 
human stroma-dependent LTBMC have a limited life span, 
and we and others (3, 4) have demonstrated that 70-80% 
of primitive progenitors capable  of reinitiating secondary 
stromal cultures (LTBMC-initiating cell [IC]) are lost over 
a period of 5 wk of culture. 
We have recently developed an alternative long-term cul- 
ture system in which hematopoietic progenitors are grown 
at a distance of the stromal layer in transwell inserts ("stroma- 
noncontact" culture) (4, 5). Cells in the transwell cannot phys- 
ically interact with stromal cells present in the bottom well 
underneath the transweU, but diffusible factors can freely pass 
the 0.4-/~m filter membrane We have demonstrated that primi- 
tive CD34 +/DR- cells grown in such cultures can not only 
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dements, but that significantly more LTBMC-IC can be re- 
covered from these cultures than from stromal cultures in 
which the hematopoietic ceils are cultured in direct contact 
with the stromal layers. However, the recovery of LTBMC-IC 
at week 5 of culture is still not >50% of the originally seeded 
LTBMC-IC. To improve the recovery of  LTBMC-IC in vitro, 
we have previously examined the effect of various,  known 
growth-promoting cytokines, including IL-1,  IL-3,  IL-6, 
G-CSF, GM-CSF, leukemia inhibitory factor (LIF), and stem 
cell factor (SCF), on the recovery of  LTBMC-IC from stroma- 
noncontact cultures (5). Although several of these cytokines 
improve the total cell expansion and production of committed 
progenitors in these cultures, none of the tested cytokines, 
either alone or in combination, were able  to increase  the 
number of LTBMC-IC present after 5 wk. 
Macrophage  inflammatory protein  lot  (MIP-lo  0'  also 
termed stem cell inhibitor (6, 7), is an 8-kD chemokine pro- 
duced by macrophages, T  lymphocytes, and bone marrow 
(BM) stromal cells (7). MIP-la reversibly inhibits the prolifer- 
ation of murine day 12-CFU-S and CFU-A both in vitro 
and in vivo (6,  8).  In humans, MIP-lol reversibly  inhibits 
the proliferation of CFU-granulocyte, erythrocyte, macro- 
phage, megakaryocyte (GEMM), burst forming unit-erythroid 
(BFU-E), and CFU-GM, whereas more mature CFU-E and 
single lineage CFU-G and CFU-M progenitors (9,  10) are 
stimulated. These studies suggest that MIP-lo~ may have an 
important role in maintaining immature hematopoietic pro- 
genitors in a quiescent state. Since loss of primitive progen- 
itors from ex vivo long-term cultures may be the result of 
excessive stimulation of the usually quiescent primitive he- 
matopoietic compartment resulting in their irreversible ter- 
minal differentiation, we elected to evaluate the effect of MIP- 
lol on the recovery of immature LTBMC-IC from long-term 
stroma-noncontact cultures. 
Materials and Methods 
Cell Separations 
BM was  aspirated from  the  posterior  iliac crest in  heparin 
from healthy young volunteers after informed consent. Primitive 
CD34 +/HLA-DR- cells (DR- cells) were purified by sequential 
Ficoll-Hypaque centrifugation (s.g. 1077) (Sigma Chemical Co., 
St. Louis, MO), counterflow centrifugation elutriation (11, 12), 
depletion oft lymphocytes  and NK cens  by sheep erythrocyte  roset- 
ting (13), and depletion  of  committed lymphoid and mydoid/mono- 
cytic  cells  using immunomagnetic  beads and anti-CD11b, anti-CD19 
(Becton Dickinson & Co., Mountain View, CA), anti-MY8 (Coul- 
ter Cytometry, Hialeah, FL) and anti-glycophorin-A antibodies 
(AMAC, Inc., Westbrook, ME) (14). The resultant lineage-negative 
cells were selected on a FACStar  Plus  |  laser flow cytometry system 
(Becton Dickinson & Co.) equipped with a Consort 32 computer 
for low vertical and low horizontal light scatter properties and ex- 
pression of CD34, but absence of HLA-DR antigens using mouse 
IgGI-PE and mouse IgG2a-FITC antibodies as controls (14). 
Long-term Culture Systems 
Complete LTBMC media consisted  of IMDM with 12.5  % FCS 
(Hyclone  Laboratories,  Logan, UT), 12.5% horse serum (Terry Fox 
Laboratories, Vancouver, Canada), 2 mM L-glutamine (GIBCO 
BRL, Gaithersburg, MD), 1,000 U/ml penicillin, 100 U/ml strep- 
tomycin (GIBCO BRL), and 10 .6 M hydrocortisone (14). 
Stroma-free Culture~  DR- cells were suspended in transwell in- 
serts (14  x  103/5 ml for 6-well phtes) placed  in stroma-free  wells. 
Culture  media consisted of complete LTBMC media with or 
without cytokines. 
Stroma-noncontact Cultures.  Transwell cultures consisted of al- 
logeneic irradiated stromal cells subcultured in the bottom well 
of 6- (1.75 x  106 cells suspended  in 3 ml) or 24- (0.35 x  106 cells 
suspended in 0.8 ml) well plates. A colhgen-treated transwell in- 
sert (0.4-~m microporous filter) (Costar Corp., Cambridge, MA) 
was then placed above the stromal layer, and sorted DR-  cells 
plates in the upper wells (2  x  103 cells/well of 24-well plates, or 
4.5-14  x  10  ~ DR- cells/5 ml of 6-well plates). 
Conditioned Media Cultures.  DR-  cells (14,000 calls/well of 
6-well plates) were plated in transwell inserts of stroma-free wells. 
Culture media for these cultures consisted of stroma-conditioned 
media obtained from "1"-150 flasks  containing irradiated anogeneic 
stromal hyers. Media was transferred  from the flask to the hemato- 
poietic cell containing wells 2, 4, and 7 d after feeding the stroma- 
containing  culture vessd. Upon transfer  of  the media  from the T-150 
flask, cytokines  were added  to obtain the final  desired  concentration. 
Maintenance of Cultures.  All cultures were maintained in a hu- 
midified atmosphere at 37~  and 5% CO2. At weekly intervals 
stroma-noncontact and stroma-free  cultures were fed by removing 
half the call-flee media from the bottom wells only and replacing 
with fresh complete media. Conditioned media cultures received 
media conditioned by allogeneic irradiated stromal layers for 2, 4, 
or 7 d after f~eding. 
Enumeration of Cell Number.  Cells  recovered from stroma-ffee, 
stroma-noncontact, or conditioned media cultures were recovered 
at week 1, 2, 3, 5, or 8 from the transwell inserts after vigorous 
washing. Calls were resuspended in IMDM plus 20% FCS, and 
an aliquot obtained for enumeration under hemocytometer. 
Enumeration of Colon]t-forming Cell (CFC) by Met~lcellulose Cul- 
ture.  Cells  harvested at week 1, 2, 3, or 5 from transwen inserts 
of stroma-noncontact cultures were plated in methylcellulose  pro- 
genitor assay supplemented with 3 IU erythropoietin (Epoietin; 
Amgen Biologicals,  Thousand Oaks, CA) and 5-10% 5637 bhdd~ 
carcinoma conditioned media as described (14). The cultures were 
assessed at day 18 of culture for the presence of secondary CFC. 
Enumeration of the Absolute Number of LTBMC-IC  by Limiting 
Dilution Assays (LDA).  At day 0, DR- cells (22 replicates per 
concentration; 400, 150, 50, and 15 DR- cells/well) were plated 
onto 3  x  104 irradiated allogeneic stromal cells or irradiated M2- 
10134 murine stromal calls subcultured in 96-well plates. Likewise, 
cells recovered after 5 or 8 wk from stroma-noncontact cultures, 
stroma-free cultures, and conditioned media cultures initiated at 
day 0 with 13,530 DR- cells were plated in LDA (cell number 
is the equivalent of 400, 150, 50, and 15 DR- calls at day 0) as 
described (4). In each  experiment, day 0 LDAs and LDAs performed 
at weeks 5 and 8 with cultured cells, were always  performed either 
on marrow stromal feeders or on M2-10B4 feeders. Cultures were 
maintained at 37~  and 5% COz in a humidified atmosphere for 
an additional 5 wk. At weekly intervals, 75 ~1 media was removed 
and replaced by 75 ml flesh complete media. At week 5, all media 
was removed  and the stromal layers  with hematopoietic cells over- 
laid with 200/~1 methylcelhlose media supplemented with 30% 
FCS, 5-10% supernatant of the bhdder cancer cell line 5637 and 
3 IU erythropoietin. 2 wk later, wells were scored  for the presence 
or absence of CFC as described (5). The absolute number  of 
LTBMC-IC present in the different  cell populations was calcuhted 
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negative cultures using the Poisson statistics (15) and the weighted 
mean method (16). 
Cytokines 
Recombinant human (rHu) ID3 (Genetics Institute, Cambridge, 
MA) was added to cultures three times per week to obtain a final 
concentration of 5 ug/ml (as indicated in the Results section), rHu 
stem cell factor (SCF) (Amgen) was added to stroma-free cultures 
three times per week to obtain a final concentration of 20 ng/ml 
(as indicated in the Results section), rHuMIP-la (R.&D Systems, 
Inc., Minneapolis, MN) was added to cultures three times per week 
to obtain a final concentration of 10, 50, or 100 ug/ml as indicated 
(concentrations were based on studies demonstrating a growth in- 
hibitory effect of 100 ug/ml MIP-la on committed human hema- 
topoietic progenitors [9,  10]). TGF-31 (R&D Systems, Inc.) was 
added once weekly 4  d  after the regular feeding.  Since  cyclical 
proliferation of immature CFC in LTBMC is thought to be the 
result of increased production of growth-promoting factors early 
after feeding fonowed by the proliferation inhibitory effects of TGr'-3 
in the second part of the week after feeding, we dected to add 
TGF-/~ 4 d after feeding only in association with IL-3 three times 
per week to mimic cytokine fluaes thought to induce cyclical prolifer- 
ation of primitive CFC in LTBMC (2). 
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Figure  1.  1-2.5  x  103 FACS  |  sorted DR- cells/m1  were cultured in 
stroma-noncontact cultures supplemented  without cytokines, MllXla (100 
ng/ml, three times per week), IL-3 (5 ng/ml, three times per week), or 
5 ng/nd IL-3 and 100 ng/ml MIlXla three times per week for 5 and 8 
wk. Cens were collected from the transwell insert and enumerated under 
hemocytometer. Fold expansion was calculated as the number of cells present 
in transwell inserts at the different time points divided by the number 
of cells used to initiate the cultures. Differences between cytokine-free or 
MIP-la-supplemented cultures and either  IL-3 or MIP-la+Ib3-sup- 
plemented cultures were significant at the <0.001 level (* *). Differences 
between cytokine-free and MIP-la-supplemented were not significant. 
Differences between IL-3 and MIP-la + II~3-supplemented cultures were 
not significant. 
Stromal Layers 
BMStromaiLayers.  BM stromal layers were generated as previ- 
ously described (15). In short, BM mononuclear cells from normal 
individuals were suspended in complete LTBMC media and in- 
cubated for 4  d  at 37~  in a humidified atmosphere with  5% 
CO2,  and  afterwards  at  33~  Cultures  were  demipopulated 
weekly and  media  replaced  with  fresh  complete media.  Once 
confluent (3-5 wk after initiation of the culture)  stromal layers 
were irradiated with 1,250  tad using a Mark-1 cesium irradiator 
(Shepard and Associates,  Glendale, CA). Stromal layers were then 
subcultured in wells of 6-, 24-, or 96-well plates before use. 
M2-10B4.  M2-10B4, a murine BM stroma cell line, was main- 
tained in R.PMI-1640 supplemented with 10% FCS. M2-10B4 was 
subcultured in the wells of a 96-well phte (Costar Corp.). When 
confluent,  plates were irradiated with 6,000 rad using a cesium 
irradiator, and all media replaced by complete LTBMC media. Ir- 
radiated plates were used 2-7 d hter. Several studies have demon- 
strated that maintenance of LTBMC-IC and their differentiation 
into CFC is similar when DR-  cells are cultured either on BM 
stromal layers or on murine M2-10B4 feeders  (3,  17). 
without  MIP-la,  IL-3, or MIP-la  plus IL-3. Cell expan- 
sion was significantly greater in stroma-noncontact cultures 
supplemented  with  IL-3  alone  or  MIP-la+IL-3  than  in 
cytokine-free cultures (Fig. 1) or cultures with MIP-la alone. 
Significantly more CFC were present in stroma-noncontact 
cultures  supplemented  with IL-3 or MIP-la+IL-3,  3  and 
5 wk after initiation of the culture (Fig. 2) than in cytokine- 
free or MIP-la  supplemented  cultures.  DR.-  derived pro- 
geny, recovered 5 wk after initiation of the stroma-noncontact 
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Statistics 
Results of experimental points obtained from multiple experi- 
ments were reported as the mean  +  1 SEM.  Significance  levels 
were determined by two-sided Student's t test analysis. 
Results  and  Discussion 
To determine if addition of MIP-la  alone or in conjunc- 
tion with  factors with  known  growth-promoting  activity 
to stroma-noncontact cultures could maintain a constant level 
of primitive human heraatopoietic progenitors in in vitro cul- 
tures,  DK-  cells,  which  contain  the LTBMC-IC (14,  18), 
and transplantable hematopoietic stem cells (19),  were cul- 
tured in stroma-noncontact  cultures  supplemented with or 
MIP-la+IL3 
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Figure  2.  FACS  ~ sorted DK- cells (n  ffi 3) were cultured in stroma- 
noncontact cultures supplemented without cytokineg MIP-la (100 ng/ml 
three times per week), II.,3 (5 ng/ml, three times per week), or II.~3 and 
MIP-la (5 and 100 ng/ml, three times per week) for 5 wk. Cens were 
collected from the transwell insert and replated in methylcelhlose progen- 
itor culture (*). The cultures were assessed at day 18 of culture for the 
presence of secondary CFC as previously described (*). Comparison be- 
tween cytokine-free and ID3-supplemented cultures: (*) p g0.01. Com- 
parison between cytokine-free  or MIP-la-supplemented cultures and MIP- 
la + 1L3-supplemented  cultures: (I) p <0.05. ~ces  between cytokine- 
free and MIP-la-supplemented cultures were not significant. Differences 
between  IL-3  and  MIP-la+Ib3-supplemented  cultures  were  not 
significant. 
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feeders to enumerate the absolute number of LTBMC-IC 
present  in  the  transwe11 inserts.  Approximately 50%  of 
LTBMC-IC present in originally sorted DR- cells were still 
present at week 5 in cytokine-ffee stroma-noncontact cul- 
tures (Fig. 3). Addition of MIP-lcx or IL3 alone to stroma- 
noncontact cultures did not significantly  change the number of 
LTBMC-IC present at week 5 compared to cytokine-ffee cul- 
tures. However, addition of the combination of  MIP-lc~ +IL3 
to stroma-noncontact cultures  resulted in the recovery of 
95-200% of the initially seeded LTBMC-IC  after 5 wk of 
culture. 
Whereas  addition  of early  acting,  growth-promoting 
cytokines,  such  as IL-3,  LIF, G-CSF, or SCF  to  stroma- 
noncontact cultures does not increase  the recovery  of  LTBMC- 
IC, combined addition of supraphysiological  amounts of these 
cytokines results in a significantly greater loss of primitive 
progenitors ow time (5). This suggests that multiple cytokines 
may overwhelm the (ill-defined) antidifferentiation effect of 
stroma-derived factors and may result in irreversible differen- 
tiation of primitive progenitors.  To determine ff continued 
presence of  high concentrations of  MIP- loc + IL-3 in stroma- 
noncontact cultures would result in a similar exhaustion of 
the primitive LTBMC-IC pool, stroma-noncontact cultures 
with or without these cytokines were maintained for 8 wk 
before replating the DR- progeny in LDA onto secondary 
stromal feeders (Fig. 3). Culture of DR- cells in cytokine- 
free stroma-noncontact cultures or cultures supplemented  with 
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MIP-lot alone for 8 rather than 5 wk resulted in an ~60% 
loss of  LTBMC-IC, which was not significantly different than 
that observed at week 5. Interestingly, culture of DR- cells 
in IL-3 supplemented stroma-noncontact cultures for 8 wk 
resulted in a significant depletion of LTBMC-IC  (<5% of 
the originally sorted DR- population). However, combined 
addition of  MIP-lot + IL-3 resulted in an imignificant decrease 
in LTBMC-IC number compared with week 5 and continued 
recovery of 80-150%  of day 0 LTBMC-IC. We demonstrate 
that addition of 10, 50, or 100 ng/ml MIP-lex with IL-3 
to stroma-noncontact cultures restdted in a similar recovery 
of LTBMC-IC  (data not shown). These results are consis- 
tent with those described by Mantel et al. (20) who recently 
demonstrated that  addition of MIP-lot at concentrations 
ranging from 10 to 500 ng/ml to methylcellulose cultures 
had equivalent effects on committed murine hematopoietic 
progenitor growth. 
The mechani.r  through which MIP-lc~ + IL-3 in stroma- 
noncontact cultures maintain primitive progenitors capable 
of reinitiating long-term cultures are unclear. Although the 
receptor for MIP-la has recently been identified as a seven 
tram-membrane spanning receptor bdongiag to the super- 
family of  G protein-linked receptors (21), the molecular mech- 
anism(s) underlying the growth-modtdating effects  of  MIP-la 
are unknown. We hypothesize  that the increased recovery 
of LTBMC-IC from cultures supplemented with MIP-la + 
IL-3 may be the result of an increased proliferation without 
terminal differentiation of LTBMC-IC.  MIP-lc~ was origi- 
nally described as "stem cell inhibitor" since it inhibits  in 
vitro and in vivo proliferation of immature CFU-A, CFU-S, 
and CFU-GEMM progenitors (6-10). Our observations may, 
however, not be the result of growth inhibition.  In contrast 
to the effect of  MIP-lot + IL-3 on LTBMC-IC recovery, com- 
bined addition of TGF-~+IL-3 to stroma-noncontact cul- 
tures resulted in a decreased  recovery of  ceils (data not shown), 
CFC (data not shown), and LTBMC-IC after 5 wk of cul- 
ture compared with cultures to which IL-3 alone was added 
(Fig. 4). It is well known that TGF-15 inhibits cell prolifera- 
tion by preventing their transition through the cell cycle (22, 
23). A direct antiproliferative effect of TGF-~ may therefore 
Figure 3.  Freshly sorted DR- cells were phted in limiting dilution 
on bone marrow stromal layers or M210-B4 feeders (22 replicates of 400, 
150, 50, and 15 cells) for 5 wk (Day 0). 14,000 DR- calls were plated 
in stroma-noncontact  cultures  supplemented  without cytokines, with 
MIP-la alone (100 ng/ml, three times per week),  Ib3 (5 ng/ml, three 
times per week), or IL,3 and MIP-lr~ (5 and 100 ng/ml, three times per 
week) for 5 and 8 wk. Cells retorted from the transwell inserts were 
then replated in LDA on either bone marrow stromal layers or M210-B4 
feeders for an additional 5 wk (cell number -  the equivalent of 400, 150, 
50, and 15 DR.- cells at day 0). After 5 wk, stromal hyers were over- 
layed  with  methylcellulose-containing  media  supplemented  with 
erythmpoietin and supernatant from the bladder CA ceil line 5637, and 
wells were scored 2 wk hter for the presence or absence of CFC and the 
absohte number of LTBMC-IC present in the different cell populations 
calenhted (*). Comparison between day 0 and week 5 is noted above the 
week 5 bars. Comparison between weeks 5 and 8 is only significant for 
cultures supplemented with IL-3. 
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Figure 4.  DR.- ceils were cultured for 5 wk in stroma-noncontact cul- 
tures supplemented without cytokines or with either ID3 alone (5 ng/ml 
three times per week) or TGF-/5+II.-3 (5 ng/rul TGF-~ once per week, 
4 d after the regular feeding and 5 ng/ml IL-3 three times per week). 
LTBMC-IC content was determined as described  in Materials and Methods. 
Comparison between cultures supplemented with IL-3 alone or cytokia~ 
free cultmx-s  and cultures supplemented with TGIL~ + IL-3, (* *)p •0.001. 
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plus IL-3-supplernented  cultures,  whereas this mechanism 
may not be operative in cultures supplemented with MIP- 
lot + IL-3. Recent in vivo studies have demonstrated that M1P- 
1r  may not maintain the mouse long-term repopulating stem 
cell, which is more primitive than the CFU-S and CFU-A 
progenitor, in a quiescent state when triggered into cycle by 
5-fluorouracil treatment  (24). These studies, together with 
data presented here indicating that addition of known prolifer- 
ation inhibitory factors such as TGF-/3 results in significantly 
decreased recovery of LTBMC-IC from stroma-noncontact 
cultures,  indicate  that  MIP-lo~ + IL-3 may not  inhibit  the 
proliferation of LTBMC-IC. Increased recovery of LTBMC-IC 
from MIP-la +IL-3 supplemented cultures could result from 
a proliferation-inducing  effect of MIP-lcx.  However, since 
addition of MIP-la without the growth-promoting cytokine 
IL-3 failed to increase the recovery of LTBMC-IC, MIP-lcx 
may not have a direct proliferation inducing effect on primi- 
tive human hematopoietic progenitors.  Prolonged stimula- 
tion of DR-  cells in stroma-noncontact cultures with IL-3 
alone results in eventual depletion of primitive LTBMC-IC 
(Fig.  3), likely as a result of their terminal differentiation. 
We believe therefore that MIP-ltx may prevent the terminal 
differentiation of immature progenitors induced to proliferate 
by relatively high levels of growth-promoting factors, such 
as IL-3, and thus result in expansion and/or accumulation 
of primitive progenitors. 
Recent studies employing a stroma-free culture system have 
demonstrated that culture of unfractionated murine marrow 
ceils or Sca+Lin -  ceils in the presence of SCF, IL-11,  and 
MIP-lcx results in a significantly greater expansion of CFU-A 
compared with cultures supplemented with SCF and IL-11 
alone (25).  To examine if stroma is required to maintain  a 
constant number of LTBMC-IC for 5-8 wk in the presence 
of M1P-lcx + IL-3, DR-  ceils were also cultured in "stroma- 
free" cultures, in which DR-  cells were suspended in trans- 
well inserts placed in empty wells. These cultures were fed 
weekly with fresh complete media, not conditioned by stromal 
layers,  and supplemented three times per week with MIP- 
1r  +IL-3+SCF.  Only 5% of LTBMC-IC present at day 0 
in freshly sorted DR-  cells were recovered from stroma-free 
cultures supplemented with MIP-lc~ +IL-3+SCF  (Fig.  5), 
indicating that additional stroma-derived soluble factors are 
synergyzing with MIP-lc~ + IL-3 to maintain a constant level 
of human LTBMC-IC in in vitro cultures. 
MIP-lc~ receptors are present on monocytes/macrophages 
(7) and MIP-lcx induces chemotaxis and oxidative burst in 
monocytes (26). Observations described here could therefore 
be the result of the induction of secondary differentiation- 
inhibitory or proliferation-inducing factors by stromal mac- 
rophages.  Addition  of MIP-lcx+IL-3  did,  however,  not 
significantly change the level of cytokines, including GM- 
CSF and IL-1/3, present in stromal  supernatants,  as deter- 
mined by ELISA (data not shown).  To examine ff the ob- 
served effects of MIP-lcx + IL-3 are the result of thdr direct 
interaction with hematopoietic progenitors or of an indirect 
effect on stromal cells,  we cultured DR-  ceils in LTBMC 
STROMA-NON-CONTACI" 
STROMA-FREE 
CONDITIONED MEDIA 
Nffi11 
N=3 )  ￿9  WITHOUT  CFTOKINE$  (*) 
lq=2 ~  []  WITH CYTOKINE$ (~) 
N=5 
N~ 
0.0  0.5  1.0  1.5  2.0 
NUMBER OF LTBMC-IC /  I00 DR- CELLS 
Figure 5.  14,000  DR- ceils  were phted in stroma-noncontact cultures 
supplemented with  (*)  or without  MIP-lc~+Ib3 (I). Alternatively, 
14,000 DR- cells were plated in stroma-free  cultures supplemented with 
SCF (20 ng/ml three times per week) and IL-3 (5 ng/ml three times per 
week) and with Q) or without (*) MIP-la (100 ng/ml three times per 
week) for 5 wk. 14,000 DR- cells  were also plated in conditioned media 
cultures. Cytokines were added to the conditioned media upon transfer 
from the stroma-containing T-150 flask to the DR- call-containing cul- 
ture vessel  to obtain the final desired concentration in those cultures with 
cytokines (I) (5 ng/ml Ib3 three times per week and 50 ng/ml MIP-ltx 
three times per week). Ceils recovered from the transweil inserts of all 
three culture systems  were  replated in LDA on either bone marrow stromal 
layers or M210-B4  feeders  for an additional 5 wk (cell number ffi the equiva- 
lent of 400, 150, 50, and 15 DR- cells  at day 0) and the absolute number 
of LTBMC-IC present in the different cell populations was calculated as 
described. 
media conditioned by allogeneic stromal layers present in a 
separate culture vessel. MIP-lot + IL-3 was added to the con- 
ditioned media when transferred to the hematopoietic cell-con- 
taining well and was therefore never in contact with the stromal 
layer.  Culture of DR-  calls in conditioned media without 
cytokines results in maintenance of an equivalent number of 
LTBMC-IC as when cultured in stroma-noncontact cultures 
(Fig. 5). When MIP-lcx + IL-3 were added to the conditioned 
media, a similar number of LTBMC-IC was present after 5 
wk of culture compared with that  in MIP-lot + IL-3 con- 
raining  stroma-noncontact  cultures (Fig.  5).  This suggests 
that MIP-lot +IL-3 exert their effect through direct interac- 
tion with DR-  cells or their progeny rather than through 
altering  the bone marrow microenvironment  milieu. 
We demonstrate for the first time that  at least 100%  of 
LTBMC-IC can be maintained  in vitro for a minimum  of 
2 mo when cultured in the presence of MIP-lol +IL-3 in 
stroma-noncontact cultures. MIP-lc~ + IL-3 require additional 
undefined diffusible factors from stroma to maintain a con- 
stant number of LTBMC-IC for 5-8 wk in culture. The effect 
of MIP-lot +IL-3 is, moreover, the result of the direct inter- 
action of MIP-lot +IL-3 with the DR-  cell population or 
its progeny, but not with the stromal layer.  It remains  to 
be seen if the addition of other carly-acting,  growth-promoting 
cytokines, such as IL-6 (11), IL-11 (27), LIF (28), SCF (29), 
or G-CSF (30), to the combination of MIP-lot,  IL-3, and 
stroma-derived factors will further expand the human primi- 
tive progenitor compartment  ex vivo, but not  trigger  the 
647  Verfaillie  et am. primitive cell compartment into irreversible terminal differen- 
tiation. The observation that a constant level of very primi- 
tive LTBMC-IC can be maintained for at least  8 wk in ex 
vivo cultures when grown in the presence of MIP-lc~, IL-3, 
and stroma-derived soluble factors  suggests a possible clin- 
ical application for such culture systems for in vitro stem cell 
expansion and retroviral gene transfection protocols. 
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